Iron Status of Non-anemic Pregnant Women in First Trimester

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

600 participants

Study Classification

OBSERVATIONAL

Study Start Date

2025-03-12

Study Completion Date

2025-08-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This cross-sectional study aims to establish reference intervals for iron biomarkers-including serum iron, ferritin, total iron-binding capacity (TIBC), and transferrin saturation (TSAT)-in healthy pregnant women during the first trimester. Additionally, the study will investigate the current prevalence of non-anemic iron deficiency (NAID) in this population. By applying strict inclusion and exclusion criteria to eliminate potential confounding factors, the study seeks to provide a reliable baseline for evaluating iron status and early detection of iron deficiency without anemia among pregnant women.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Iron Parameters in Non-anemic First Trimester Gravidas

NCT03670537

Iron Deficiency (Without Anemia) Pregnancy

COMPLETED

The Oral Iron on the Prevention of Iron Deficiency Anemia in Obese Pregnant

NCT04101461

Anemia of Pregnancy

COMPLETED NA

Iron Metabolism Parameters At First Trimester and preGnancy outcomE

NCT03176147

Iron Deficiency Anemia

UNKNOWN

Iron Deficiency Anemia in Twin Pregnancies

NCT04975074

Anemia, Iron-Deficiency

UNKNOWN PHASE4

Maternal Serum Ferritin and Low Neonatal Birth Weight

NCT02738463

IUGR

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

1. Title Reference Intervals of Iron, Ferritin, TIBC, and Transferrin Saturation in First Trimester Pregnant Women and Prevalence of Non-Anemic Iron Deficiency
2. Background and Rationale Iron deficiency (ID) is the most common micronutrient deficiency globally and a significant concern during pregnancy. Early identification of iron deficiency-even in the absence of anemia-is essential to prevent adverse maternal and fetal outcomes. However, reference intervals for iron biomarkers in early pregnancy remain inconsistent and vary across populations. Moreover, there is a paucity of data on the prevalence of non-anemic iron deficiency (NAID) during the first trimester, a critical period for fetal development. This study aims to address these gaps.
3. Objectives Primary Objective: To determine reference intervals for serum iron, ferritin, TIBC, and TSAT in healthy pregnant women during the first trimester.

Secondary Objective: To estimate the prevalence of non-anemic iron deficiency (NAID), defined as low iron biomarkers with normal hemoglobin (Hb ≥ 11 g/dL).
4. Study Design Type: Cross-sectional observational study Setting: Antenatal care clinics at Hung Vuong Hospital, Ho Chi Minh city, Vietnam Duration: From March to June, 2025 (anticipated)
5. Study Population Inclusion Criteria

* Pregnant women in the first trimester (gestational age ≤ 13 weeks 6 days).
* Carrying a single live fetus.
* Hemoglobin ≥ 11 g/dL at the time of enrollment.
* Systolic blood pressure \< 140 mmHg and diastolic \< 90 mmHg.
* Body temperature \> 35°C and \< 37.5°C at time of examination.
* Attending routine antenatal care and willing to participate. Exclusion Criteria
* History of:

Diabetes mellitus, hypertension, hemoglobinopathies, leukemia, non-hematologic malignancies, systemic lupus erythematosus. Gastrointestinal disorders affecting iron absorption (e.g., Celiac disease, Crohn's disease, ulcerative colitis, gastric surgery).
* Current use of acid-suppressing medications (PPIs, H2 blockers).
* Positive screening for Treponema pallidum, HBsAg, or HIV.
* Use of stimulants or tobacco smoking.
6. Sample Size A minimum of 120 participants is recommended for establishing reference intervals per CLSI guidelines (C28-A3), with oversampling to account for exclusions and incomplete data.
7. Data Collection Clinical Data

* Maternal age, gestational age, BMI
* Vital signs (BP, temperature)
* Medical and obstetric history Laboratory Investigations
* Hemoglobin (Hb)
* Serum iron
* Ferritin
* Total iron-binding capacity (TIBC)
* Transferrin saturation (TSAT) = (Serum iron / TIBC) × 100
8. Statistical Analysis Reference Intervals

* Outlier detection using Dixon-Reed methods
* Calculation of 2.5th-97.5th percentiles (non-parametric method) Prevalence of NAID
* Defined as ferritin \< 15 ng/mL or TSAT \< 20% with Hb ≥ 11 g/dL (or more cutoffs to present a wide variety of prevalences of NAID). Reported as frequency and percentage with 95% confidence intervals Software
* Statistical analysis will be performed using Jupyter Notebook (python programming language)
9. Ethical Considerations

* Ethical approval will be obtained from the Institutional Review Board.
* Written informed consent will be obtained from all participants.
* Data confidentiality will be strictly maintained.
10. Significance The findings will provide local reference standards for iron parameters during early pregnancy and help clinicians better detect and manage iron deficiency before the onset of anemia. This is critical for optimizing maternal and fetal health outcomes and future study to determine best intervention for NAID patients.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Iron Deficiency (Without Anemia) Reference Values Iron Deficiency Without Anemia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

With iron supplement

Pregnant women who are taking iron supplement

No interventions assigned to this group

Without iron supplement

Pregnant women who are not taking any iron supplement

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Pregnant women attending antenatal care, carrying a single live fetus.
* Systolic blood pressure at the time of examination \< 140 mmHg.
* Diastolic blood pressure at the time of examination \< 90 mmHg.
* Body temperature at the time of examination between \>35°C and \<37.5°C.
* Hemoglobin ≥ 11 g/dL

Exclusion Criteria

* History of diabetes mellitus, hypertension, hemoglobinopathies, leukemia, non-hematologic cancers, systemic lupus erythematosus, Gastrointestinal diseases (Celiac disease, Crohn's disease and ulcerative colitis, Gastric diseases or prior gastrointestinal surgery, Irritable bowel syndrome, etc).
* Currently on gastric acid-suppressing medications: Proton pump inhibitors (e.g., Omeprazole, Lansoprazole, Esomeprazole...), H2 receptor antagonists (e.g., Ranitidine, Famotidine, Cimetidine...), Positive screening for Treponema pallidum, HBsAg, or HIV.
* Use of stimulants or tobacco smoking.

Minimum Eligible Age

18 Years

Maximum Eligible Age

45 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes